Astellas Pharma

Astellas Pharma reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 March 2021 at 123 Kt (-44 /-26.2% y-o-y). Also positively, carbon intensity decreased to 14 t (-1.6 /-10.1% y-o-y).

Astellas Pharma's Scope 3 emissions plunged to 194 Kt (-33 /-14.5% y-o-y). The decline accelerated compared to the CAGR of -5.2% since 1Q'19.

The company is committed to reducing Scope 1 + 2 by 30% by 2031 from a base year 2021, which translates into the estimated reduction of -3.7 Kt per annum over the period of FY2022 - FY2031. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Astellas Pharma also has a science-based goal that, however, does not appear to explicitly target a company-wide reduction in emissions in absolute terms. Japanese pharmaceutical company Astellas Pharma Inc. commits to reduce absolute Scope 1 and 2 GHG emissions 30% by 2030 from a 2015 base-year. Astellas Pharma Inc. also commits to reduce Scope 3 GHG emissions 20% per JPY of revenue by 2030 from a 2015 base-year.